18 May 2013
Keywords: zeltia, yondelis, enters, phase, iii, value, spanish
Article | 11 April 2005
The value of the Spanish Zeltia group rose 1.3% on the Madrid stock exchange after announcing that its ovarian cancer agent, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 April 2005
17 May 2013
© 2013 thepharmaletter.com